


Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance

In the article on how IGF-IR/HER-2 contributes to trastuzumab resistance in the December 1, 2005 issue of *Cancer Research* (1), Fig. 2A is incorrect. The corrected panel appears below.



1. Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. *Cancer Res* 2005;65:11118–28.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance

Cancer Res 2008;68:9566.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/68/22/9566.1>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/68/22/9566.1.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/68/22/9566.1>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.